Boston Family Office LLC Sells 437 Shares of Hologic, Inc. (NASDAQ:HOLX)

Boston Family Office LLC decreased its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 2.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 18,997 shares of the medical equipment provider’s stock after selling 437 shares during the period. Boston Family Office LLC’s holdings in Hologic were worth $1,547,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Wolff Wiese Magana LLC acquired a new stake in shares of Hologic in the 3rd quarter worth about $25,000. Innealta Capital LLC purchased a new stake in shares of Hologic in the second quarter worth approximately $25,000. iA Global Asset Management Inc. bought a new position in shares of Hologic in the first quarter valued at approximately $37,000. First Horizon Advisors Inc. boosted its position in shares of Hologic by 38.3% during the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock valued at $39,000 after buying an additional 134 shares during the last quarter. Finally, Sunbelt Securities Inc. purchased a new stake in Hologic in the 2nd quarter valued at $37,000. 94.73% of the stock is owned by institutional investors.

Hologic Stock Performance

NASDAQ HOLX opened at $78.97 on Monday. The firm has a market cap of $18.34 billion, a P/E ratio of 23.71, a price-to-earnings-growth ratio of 2.49 and a beta of 0.98. The company has a quick ratio of 3.03, a current ratio of 3.69 and a debt-to-equity ratio of 0.49. The company’s 50 day moving average is $80.44 and its 200-day moving average is $78.35. Hologic, Inc. has a 12-month low of $67.59 and a 12-month high of $84.67.

Hologic (NASDAQ:HOLX) last issued its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.01. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The business had revenue of $987.90 million for the quarter, compared to analysts’ expectations of $978.25 million. During the same quarter in the previous year, the firm posted $0.89 EPS. The business’s revenue for the quarter was up 4.5% compared to the same quarter last year. Sell-side analysts predict that Hologic, Inc. will post 4.27 earnings per share for the current year.

Analyst Upgrades and Downgrades

HOLX has been the topic of a number of analyst reports. UBS Group lifted their price objective on shares of Hologic from $84.00 to $90.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Raymond James lifted their target price on shares of Hologic from $93.00 to $95.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 5th. Stephens restated an “overweight” rating and issued a $92.00 target price on shares of Hologic in a research note on Tuesday, July 30th. StockNews.com upgraded Hologic from a “hold” rating to a “buy” rating in a report on Thursday, November 14th. Finally, Royal Bank of Canada raised their target price on Hologic from $86.00 to $89.00 and gave the company a “sector perform” rating in a research report on Tuesday, November 5th. Four research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, Hologic currently has a consensus rating of “Moderate Buy” and an average target price of $89.91.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.